Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Hologic (HOLX)
NASDAQ:HOLX
Holding HOLX?
Track your performance easily
HOLX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$68.61 - $84.67
Previous CloseN/A
Volume386.02K
Average Volume (3M)2.65M
Market Cap
$15.88B
Enterprise Value$19.40B
Total Cash (Recent Filing)$540.60M
Total Debt (Recent Filing)$2.23B
Price to Earnings (P/E)21.0
Beta0.38
Next Earnings
Feb 05, 2025EPS Estimate
1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.32
Shares Outstanding226,941,220
10 Day Avg. Volume2,982,500
30 Day Avg. Volume2,653,282
Standard Deviation0.09
R-Squared0.29
Alpha-0.00157
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.94
Price to Cash Flow (P/CF)10.80
P/FCF Ratio10.60
Enterprise Value/Market Cap1.22
Enterprise Value/Revenue4.81
Enterprise Value/Gross Profit8.71
Enterprise Value/Ebitda45.86
Forecast
1Y Price Target
$86.38Price Target Upside23.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
Hologic News
PremiumCompany Announcements
Hologic Announces Board of Directors Changes
Bulls Say, Bears Say
Bulls Say
Diagnostics PerformanceDiagnostics grew above consensus, showing strong performance excluding COVID sales.
Earnings PerformanceHologic expects its EPS to be toward the high-end of its previous guidance.
Product EndorsementNewly released draft USPSTF cervical cancer screening recommendations maintain cotesting as a Grade A recommended test, benefiting Hologic's market-leading AptimaHPV/ThinPrep test.
Bears Say
Breast Health SegmentBreast Health underperforms with organic growth excluding SSI and Endomagnetics at -5.8%.
Financial PerformanceHologic's preannouncement showed revenue below consensus and its own guidance.
Growth PotentialA discount to peers is warranted, leaving limited upside potential for the stock.
---
Ownership Overview
1.38% Insiders
30.51% Mutual Funds
0.51% Other Institutional Investors
38.67% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HOLX FAQ
What was Hologic’s price range in the past 12 months?
Hologic lowest stock price was $68.61 and its highest was $84.67 in the past 12 months.
What is Hologic’s market cap?
Hologic’s market cap is $15.88B.
When is Hologic’s upcoming earnings report date?
Hologic’s upcoming earnings report date is Feb 05, 2025 which is in 14 days.
How were Hologic’s earnings last quarter?
Hologic released its earnings results on Nov 04, 2024. The company reported $1.01 earnings per share for the quarter, missing the consensus estimate of $1.013 by -$0.003.
Is Hologic overvalued?
According to Wall Street analysts Hologic’s price is currently Undervalued.
Does Hologic pay dividends?
Hologic does not currently pay dividends.
What is Hologic’s EPS estimate?
Hologic’s EPS estimate is 1.01.
How many shares outstanding does Hologic have?
Hologic has 226,941,220 shares outstanding.
What happened to Hologic’s price movement after its last earnings report?
Hologic reported an EPS of $1.01 in its last earnings report, missing expectations of $1.013. Following the earnings report the stock price went down -5.877%.
Which hedge fund is a major shareholder of Hologic?
Among the largest hedge funds holding Hologic’s share is Gotham Asset Management LLC. It holds Hologic’s shares valued at 20M.
---
Hologic Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$86.38 (23.88% Upside)
$86.38 (23.88% Upside)
Blogger Sentiment
Bullish
HOLX Sentiment 75%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 26.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.54%
12-Months-Change
Fundamentals
Return on Equity
15.56%
Trailing 12-Months
Asset Growth
0.18%
Trailing 12-Months
Company Description
Hologic
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following business segments: Breast Health, Diagnostics, Medical Aesthetics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a broad portfolio of breast imaging and related products and accessories, including digital mammography systems, computer-aided detection, for mammography and minimally invasive breast biopsy devices, breast biopsy site markers, and breast biopsy guidance systems. The Diagnostics segment comprises Aptima family of Assays, target capture/nucleic acid extraction techonolgy, transcription-mediated amplification technology, hybridization protection assay and dual kinetic assat technologies, instrumentation, and Invader Chemistry Platform. The Medical Aesthetics segment offers SculpSure; PicoSure, MedLite, and RevLite; and MonaLisa Touch. The GYN Surgical segment encompasses the NovaSure Endometrial Ablation System and the MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment covers the discovery and horizon X-ray bone densitometry system, an ultrasound-based osteoporosis assessment product, and Fluoroscan mini C-arm imaging products. The company was founded by S. David Ellenbogen and Jay A. Stein in 1986 and is headquartered in Marlborough, MA.
---
HOLX Company Deck
---
HOLX Earnings Call
Q4 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted robust financial performance, successful growth in key segments like Molecular Diagnostics, and strategic M&A activities. However, challenges such as temporary headwinds in the Skeletal business, anticipated normalization in Breast Health growth, and external factors like IV fluid shortages were noted. Despite these challenges, the company's strong balance sheet and international growth prospects indicate a positive outlook.Read More>---
HOLX Revenue Breakdown
44.22% Diagnostics
37.79% Breast Health
15.91% GYN Surgical
2.09% Skeletal Health
---
HOLX Stock 12 Month Forecast
Average Price Target
$86.38
▲(23.88% Upside)
Technical Analysis
Dexcom
―
Intuitive Surgical
―
Idexx Laboratories
―
Align Tech
―
Bio-Rad Laboratories
―
Thermo Fisher
―
Best Analysts Covering HOLX
1 Year
1 Year Success Rate
8/20 ratings generated profit
1 Year Average Return
-0.10%
reiterated a buy rating 10 days ago
Copying Puneet Souda's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -0.10% per trade.
---